Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (27 quarters reported)
$100M in Q4 2018 → $1.1B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PM Parabilis Medicines Inc | 16.0% | New | 6,412,780 | $176M |
| Beam Therapeutics Inc | 14.2% | Unchanged | 4,540,132 | $156M |
| Rapport Therapeutics Inc | 14.1% | Unchanged | 3,728,738 | $155M |
| Seaport Therapeutics Inc | 12.4% | New | 6,294,951 | $137M |
| Erasca Inc | 11.8% | Unchanged | 7,091,557 | $130M |
| Vir Biotechnology Inc | 11.8% | Trimmed 1.7% | 12,694,163 | $129M |
| Maze Therapeutics Inc | 11.2% | Unchanged | 4,120,053 | $123M |
| Lyell Immunopharma Inc | 4.1% | Unchanged | 3,247,162 | $45.5M |
| Generate Biomedicines Inc | 3.0% | Unchanged | 1,944,426 | $32.8M |
| 10x Genomics Inc | 0.8% | Unchanged | 217,834 | $8.35M |
| Boundless Bio Inc | 0.6% | New | 2,694,095 | $6.74M |
| Gossamer Bio Inc | 0.1% | Unchanged | 8,055,916 | $1.33M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PM Parabilis Medicines Inc | New | +6,412,780 | +$176M | 16.0% |
| Seaport Therapeutics Inc | New | +6,294,951 | +$137M | 12.4% |
| Boundless Bio Inc | New | +2,694,095 | +$6.74M | 0.6% |
| Vir Biotechnology Inc | Trimmed | −222,500 | −$2.27M | 11.8% |
| Q32 Bio Inc | Exited | −320,482 | −$2.06M | — |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Erasca Inc | Trimmed | −3,963,997 | −$64.1M | 16.9% |
| Generate Biomedicines Inc | New | +1,944,426 | +$24.3M | 3.6% |
| 10x Genomics Inc | Trimmed | −519,705 | −$11M | 0.7% |
| Lyell Immunopharma Inc | Added | +488,090 | +$9.79M | 9.6% |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 10x Genomics Inc. | New | +737,539 | +$12M | 1.8% |
| Cero Therapeutics Holdings Inc. | Exited | −22,389 | −$114K | — |
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Verve Therapeutics Inc. | Exited | −2,008,809 | −$22.6M | — |
| Lyell Immunopharma Inc. | Added | +938,438 | +$15.2M | 9.1% |
| Unity Biotechnology Inc. | Exited | −1,004,817 | −$386K | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vir Biotechnology Inc. | New | +12,916,663 | +$65.1M | 21.8% |
| Lyell Immunopharma Inc. | New | +1,820,634 | +$16.1M | 5.4% |
| Cero Therapeutics Holdings Inc. | New | +22,389 | +$216K | 0.1% |
| Cero Therapeutics Holdings, Inc. | Exited | −22,102 | −$16.1K | — |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Maze Therapeutics, Inc. | New | +4,120,053 | +$45.4M | 22.0% |
| Singular Genomics Systems, Inc. | Exited | −126,630 | −$2.46M | — |
| Cero Therapeutics Holdings, Inc. | Exited | −9,393,561 | −$564K | — |
| Cero Therapeutics Holdings, Inc. | New | +22,102 | +$16.1K | — |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Beam Therapeutics Inc. | Trimmed | −294,521 | −$7.3M | 48.9% |
| Cero Therapeutics Holdings, Inc. | Added | +7,949,265 | +$477K | 0.2% |
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Beam Therapeutics Inc. | Trimmed | −608,386 | −$14.9M | 45.5% |
Loading...
